Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Non-Current Assets (2017 - 2025)

Dianthus Therapeutics (DNTH) has 7 years of Non-Current Assets data on record, last reported at $163.6 million in Q3 2025.

  • For Q3 2025, Non-Current Assets rose 145.09% year-over-year to $163.6 million; the TTM value through Sep 2025 reached $396.8 million, up 439.68%, while the annual FY2024 figure was $93.1 million, 4664.79% up from the prior year.
  • Non-Current Assets reached $163.6 million in Q3 2025 per DNTH's latest filing, up from $62.5 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $163.6 million in Q3 2025 and bottomed at $1.0 million in Q3 2023.
  • Average Non-Current Assets over 4 years is $44.0 million, with a median of $33.1 million recorded in 2022.
  • Peak YoY movement for Non-Current Assets: crashed 96.85% in 2023, then soared 6516.35% in 2024.
  • A 4-year view of Non-Current Assets shows it stood at $1.1 million in 2022, then surged by 81.43% to $2.0 million in 2023, then surged by 4664.79% to $93.1 million in 2024, then soared by 75.74% to $163.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were $163.6 million in Q3 2025, $62.5 million in Q2 2025, and $77.6 million in Q1 2025.